❌

Normal view

Received — 13 February 2026 ⏭ Favourites
  • ✇InfoQ
  • OpenAI Scales Single Primary Postgresql to Millions of Queries per Second for ChatGPT Leela Kumili
    OpenAI described how it scaled PostgreSQL to support ChatGPT and its API platform, handling millions of queries per second for hundreds of millions of users. By running a single-primary PostgreSQL deployment on Azure with nearly 50 read replicas, optimizing query patterns, and offloading write-heavy workloads to sharded systems, OpenAI maintained low-latency reads while managing write pressure. By Leela Kumili
     
  • 🏷️
  • ↗️

OpenAI Scales Single Primary Postgresql to Millions of Queries per Second for ChatGPT

✇InfoQ
By: Leela Kumili
12 February 2026 at 23:00

OpenAI described how it scaled PostgreSQL to support ChatGPT and its API platform, handling millions of queries per second for hundreds of millions of users. By running a single-primary PostgreSQL deployment on Azure with nearly 50 read replicas, optimizing query patterns, and offloading write-heavy workloads to sharded systems, OpenAI maintained low-latency reads while managing write pressure.

By Leela Kumili
  • ✇STAT
  • STAT+: Researchers take another look at Apple’s hypertension feature Mario Aguilar
    You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday. Good morning health tech readers! Today, we’ve got a ton of updates including news about venture capital funding, telehealth policy, the government’s progress on information blocking, and research into the accuracy of Apple’s new hypertension feature.Continue to STAT+ to read the full story…
     
  • 🏷️
  • ↗️

STAT+: Researchers take another look at Apple’s hypertension feature

✇STAT
By: Mario Aguilar
12 February 2026 at 21:42

You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday.

Good morning health tech readers!

Today, we’ve got a ton of updates including news about venture capital funding, telehealth policy, the government’s progress on information blocking, and research into the accuracy of Apple’s new hypertension feature.

Continue to STAT+ to read the full story…

© Business Wire via AP

Upconversion mesoporous silica nanoparticles co-delivering celecoxib and rose bengal enable multimodal immunogenic and anti-angiogenic therapy for spinal metastasis of non-small cell lung cancer

✇(Multiomics OR Omics) AND (Lung OR gastric OR Hepatocellular)
By: Xinxin Li · Shuangmei Liu · Ruoyu Wang · Xinlei Wang
11 February 2026 at 19:00

Oncogene. 2026 Feb 11. doi: 10.1038/s41388-026-03679-y. Online ahead of print.

ABSTRACT

Non-small cell lung cancer (NSCLC) with spinal metastasis represents a clinical challenge due to its aggressive nature, limited treatment options, and profound impact on patient quality of life. Here, we report the development of an innovative upconversion mesoporous silica nanoparticle (UCMS) platform co-loaded with celecoxib and rose bengal (UCMS@CXB/RB), engineered to synergistically combine photodynamic therapy (PDT) and cyclooxygenase-2 (COX-2) inhibition. Upon near-infrared (NIR) irradiation, UCMS@CXB/RB generated abundant reactive oxygen species, triggered immunogenic cell death, and significantly suppressed prostaglandin E2 signaling, leading to reduced angiogenesis and improved antitumor immunity. In vitro and in vivo studies confirmed that this nanoplatform effectively remodeled the tumor microenvironment, inhibited tumor growth, and alleviated cancer-induced spinal dysfunction. Single-cell multi-omics analysis further revealed dynamic crosstalk among immune cells, tumor cells, and endothelial populations, providing mechanistic insights into the multifaceted therapeutic effects of UCMS@CXB/RB. Our results underscore the clinical potential of integrating PDT with targeted COX-2 blockade to address the complex pathophysiology of NSCLC spinal metastasis. This study presents a promising minimally invasive therapeutic strategy with strong translational relevance for managing metastatic NSCLC and improving patient outcomes.

PMID:41673094 | DOI:10.1038/s41388-026-03679-y

There are no more articles
❌